Education
About Us
Working with TipRanks
Follow Us
Tenax Therapeutics (TENX)
NASDAQ:TENX
Total Valuation
Tenax Therapeutics has a market cap or net worth of $73.61M. The enterprise value is $203.06M.
Market Cap$73.61M
Enterprise Value$203.06M
Share Statistics
Tenax Therapeutics has 6,243,575 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,243,575
Owned by Insiders0.35%
Owned by Institutions50.96%
Financial Efficiency
Tenax Therapeutics’s return on equity (ROE) is -0.19 and return on invested capital (ROIC) is -21.19%.
Return on Equity (ROE)-0.19
Return on Assets (ROA)-0.18
Return on Invested Capital (ROIC)-21.19%
Return on Capital Employed (ROCE)-0.21
Revenue Per Employee0.00
Profits Per Employee-4.40M
Employee Count4
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Tenax Therapeutics is ―. Tenax Therapeutics’s PEG ratio is 0.06.
PE Ratio―
PS Ratio0.00
PB Ratio1.03
Price to Fair Value1.03
Price to FCF-6.38
Price to Operating Cash Flow-14.66
PEG Ratio0.06
Income Statement
In the last 12 months, Tenax Therapeutics had revenue of 0.00 and earned -17.60M in profits. Earnings per share was -1.15.
Revenue0.00
Gross Profit0.00
Operating Income-19.49M
Pretax Income-17.60M
Net Income-17.60M
EBITDA-17.58M
Earnings Per Share (EPS)-1.15
Cash Flow
In the last 12 months, operating cash flow was -25.91M and capital expenditures 3.00, giving a free cash flow of -25.91M billion.
Operating Cash Flow-25.91M
Free Cash Flow-25.91M
Free Cash Flow per Share-4.15
Dividends & Yields
Tenax Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.77
52-Week Price Change133.51%
50-Day Moving Average8.34
200-Day Moving Average6.64
Relative Strength Index (RSI)86.00
Average Volume (3m)77.07K
Important Dates
Tenax Therapeutics upcoming earnings date is Mar 26, 2026, TBA (Confirmed).
Last Earnings DateNov 12, 2025
Next Earnings DateMar 26, 2026
Ex-Dividend Date―
Financial Position
Tenax Therapeutics as a current ratio of 20.60, with Debt / Equity ratio of 0.00%
Current Ratio20.60
Quick Ratio20.60
Debt to Market Cap0.00
Net Debt to EBITDA5.40
Interest Coverage Ratio-847.57
Taxes
In the past 12 months, Tenax Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Tenax Therapeutics EV to EBITDA ratio is 0.02, with an EV/FCF ratio of 0.02.
EV to Sales0.00
EV to EBITDA0.02
EV to Free Cash Flow0.02
EV to Operating Cash Flow0.02
Balance Sheet
Tenax Therapeutics has $99.37M in cash and marketable securities with $0.00 in debt, giving a net cash position of $99.37M billion.
Cash & Marketable Securities$99.37M
Total Debt$0.00
Net Cash$99.37M
Net Cash Per Share$15.92
Tangible Book Value Per Share$6.02
Margins
Gross margin is 50.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin50.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Tenax Therapeutics is $25.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$25.00
Price Target Upside95.01% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast92.89%